'At this time, there is no rapid, point-of-care test available in the US that clinicians can use to help distinguish a bacterial respiratory infection from a viral infection.'
That is the key takeaway.
This will be so huge if Lumos can get the FDA approval. Fingers crossed.
Ann: Lumos Files Appeal To The FDA For FebriDx, page-2
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
